

Quality

We provide active pharmaceutical ingredients and drug products based on our fully integrated global manufacturing capabilities. Building on our unique skills in fermentation, synthesis and biotechnology all our products meet the highest quality standards.

For us, quality means more than just compliance with current Good Manufacturing Practices (cGMP). We have a comprehensive set of Quality and Safety, Health and Environment (SHE) policies that go beyond cGMP and which we apply globally – not only to ourselves but also to our manufacturing partners. These policies are supported by our membership to the PSCI and Together for Sustainability (TfS) initiative.

Combining these standards with our unique technology platform allows us to provide the world with life-saving medicines, which are safe and effective, in a sustainable and responsible way.

Reliability

We are known as the reliable, long-term partner in our industry. Our customers and marketing partners can count on us to deliver the solutions and high-quality products they need – at the right time and place, and in the right quality and quantity.

Our supply chain for key intermediates is largely backward integrated. In addition, we work with trusted suppliers with whom we have longstanding relationships. Customers can rest assured that the origin and traceability of our products are impeccable, as are the quality and sustainability with which they have been manufactured and processed.

Our production is supported by multiple plants across the globe and by operations in each of our regions. All our sites meet (and often exceed) the highest local and international standards.

Sustainability

To measure our progress in creating sustainable value, we map our efforts along three dimensions: People, Planet and Profit. We are pioneers of the most eco-friendly technologies and production processes for APIs, such as our unique enzymatic technology, proven by 500 individual patents.

Our Sustainable Antibiotics Program provides a comprehensive platform through which we address serious global issues related to the manufacturing and use of antibiotics, and aim to increase the sustainability of our industry as a whole.

Contact and information

For more information, please visit
www.dsm-sinochem.com or e-mail
licensing@dsm-sinochem.com

Copyright © 2018 DSM Sinochem Pharmaceuticals. All rights reserved.

Although all reasonable and diligent care has been used to ensure that the information provided herein is accurate, nothing contained herein shall, or may, be construed to imply any representation or warranty as to the accuracy, currency or completeness of this information nor shall it be construed to imply any other representation or warranty of any kind, including the implied warranties of merchantability, fitness for a particular purpose or non-infringement. DSP has no obligation to update the statements contained in this presentation, unless required by applicable law. The content of this document is subject to change without any notice. Product offers are explicitly not made in respect of those jurisdictions where valid third party patent rights related to such products are in force. In such jurisdictions the advertised products are only offered for regulatory purposes insofar allowed under local provisions such as the Bolar provisions in the US and 2004/27/EC in Europe.

VDPP17042018



Drug products
portfolio



SINOCEM



DSM

DSM Sinochem Pharmaceuticals

DSM Sinochem Pharmaceuticals

Founded in 1869, DSM Sinochem Pharmaceuticals (DSP) looks back at over 140 years of innovation, from fermentation and microbiology in the late 1800s, over penicillin production development in the 1940s, the enzymatic revolution in antibiotic production in the 2000s to new state-of-the-art formulations for generic pharmaceuticals today.

We are a B2B provider of active pharmaceutical ingredients (APIs) and generic drug products. What sets DSP apart is our full backward integration and control of our supply chain. Our high quality APIs, the PureActives®, deliver unique quality and performance in the finished dosage formulation.

On the basis of our unique APIs, we offer our marketing partners a one-stop shop solution for worry-free generic drug products. Based on our vertically integrated production capabilities and paired with our extensive regulatory know-how and services, doing business with us enables you to focus on what truly counts: your business and your customers.

Our global network

Global mindset

Our global corporate staff provides our strong regional units with solid support. This setup allows us to act in a coordinated way on a global level, while keeping a bird's eye perspective that helps us to constantly improve our products and services.

Local presence












Four regional units and one global unit for drug products are the cornerstones of our customer and supplier relationships. Together, they span the entire globe. Individually, they are close to you – our valued partners.

PureActives® – the enzymatic difference

Fulfilling our duty to protect end users and the environment is something we take very seriously. We have reduced our waste products and greenhouse gas emissions significantly in recent years. Today, we are proud that our PureActives® are the world's purest and most environmentally friendly produced APIs and drug products.

DSP's enzymatic platform completely replaces the traditional 13-step antibiotic production process with natural processes that eliminate the use of solvents or other chemicals. Most of the chemical steps in producing our statins have been replaced with enzymatic processes as well.

Our drug products portfolio

Molecule	Dosage form	Strength	Dossier type*	Climatic Zone IV
Beta-lactams 				
Amoxicillin	 Capsules, hard	250 mg 500 mg	EU - CTD	-
	 Dispersible tablets, Tablets	500 mg 750 mg 1,000 mg	EU - CTD	-
	 Powder for oral suspension	125 mg / 5 ml 250 mg / 5 ml 500 mg / 5 ml	EU - CTD	-
Amoxicillin + Clavulanic acid	 Film-coated tablet	250 mg + 125 mg (2:1) 500 mg + 125 mg (4:1) 875 mg + 125 mg (7:1)	EU - CTD	In process
		500 mg + 62.5 mg (8:1)		-
	 Powder for oral suspension	125 mg + 31.25 mg (4:1) / 5ml 400 mg + 57 mg (7:1) / 5ml 250 mg + 62.5 mg (4:1) / 5ml 600 mg + 42.9 mg (14:1) / 5ml	EU - CTD Q3 2018	Start of stability studies: Q4 2017
		200 mg + 28.5 mg (7:1) / 5ml	EU - CTD under development	-
		500 mg + 62.5 mg (8:1) / 5ml	EU - CTD	-
	 Powder for oral suspension in sachet	500 mg + 125 mg (4:1) 875 mg + 125 mg (7:1)	EU - CTD	In process
1,000 mg + 125 mg (8:1)		EU - CTD	-	
Statins 				
Atorvastatin	 Film-coated tablet	10 mg 40 mg 20 mg 80 mg	EU - CTD (US-CTD under development)	Start of stability studies: Q2 2018
		30mg 60mg	EU - CTD	-
Rosuvastatin	 Film-coated tablet	5 mg 20 mg 10 mg 40 mg	EU - CTD	Available
		15mg 30mg	EU - CTD (Start of stability studies: Q2 2018)	-
Anti-Fungals				
Caspofungin	 Powder for concentrate for solution for infusion	50 mg 70 mg	EU - CTD	Available - cold chain product

*Dossiers available for world-wide filling. Availability of worldwide dossiers is dependent on local regulatory requirements